project id: TCGA-BLCA; case submitter id: TCGA-HQ-A5ND; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.74; rna integrity number: 8.4; age at index: 78; days to birth: -28555; days to death: 274; ethnicity: not reported; gender: male; race: not reported; vital status: Dead; age at diagnosis: 28555; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T3b; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; alcohol history: Not Reported; cigarettes per day: 2.191780821917808; pack years smoked: 40.0; is ffpe: false; composition: Not Reported; days to sample procurement: 0; initial weight: 560.0; portion submitter id: TCGA-HQ-A5ND-01A-11; percent lymphocyte infiltration: 7.0; percent monocyte infiltration: 2.0; percent necrosis: 4.0; percent neutrophil infiltration: 2.0; percent normal cells: 0.0; percent stromal cells: 45.0; percent tumor cells: 51.0; percent tumor nuclei: 80.0;